Related Experiment Videos
Lipid-lowering response to statins is affected by CYP3A5 polymorphism
Kari T Kivistö1, Mikko Niemi, Elke Schaeffeler
1Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Pharmacogenetics
|July 31, 2004
Summary
Individuals with the CYP3A5 enzyme expressor genotype show a reduced response to statins like atorvastatin. This genetic factor may impact cholesterol-lowering efficacy, suggesting personalized medicine approaches for statin therapy.
Area of Science:
- Pharmacogenomics
- Clinical Chemistry
Background:
- The cytochrome P450 3A5 (CYP3A5) enzyme plays a role in drug metabolism.
- Genetic variations in CYP3A5 may influence the efficacy of certain medications, including statins.
Purpose of the Study:
- To investigate the association between CYP3A5 expression and the lipid-lowering response to statins in Caucasian patients.
- To determine if CYP3A5 expressors exhibit an impaired response to specific statins.
Main Methods:
- Study included 69 Caucasian patients undergoing statin therapy.
- Patients were genotyped for CYP3A5 polymorphism (CYP3A5*1 allele vs. CYP3A5*3 allele).
- Lipid profiles (total cholesterol, LDL cholesterol) were monitored, and statin efficacy was assessed.
Main Results:
- Statins metabolized by CYP3A5 (lovastatin, simvastatin, atorvastatin) were less effective in CYP3A5 expressors.
- CYP3A5 expressors had significantly higher total cholesterol (23%) and LDL cholesterol (24%) levels after one year.
- The percentage reduction in total cholesterol was significantly lower in CYP3A5 expressors (17%) compared to non-expressors (31%).
- No significant association was found for statins not dependent on CYP3A5 (fluvastatin, pravastatin).
Conclusions:
- CYP3A5 genotype is associated with interindividual variability in response to CYP3A5-dependent statins.
- CYP3A5 expressors may require alternative lipid-lowering strategies.
- Genetic profiling of CYP3A5 could inform personalized statin therapy.